alina: evaluating the safety of adjuvant alectinib for alk nsclc
Published 2 months ago • 41 plays • Length 0:37Download video MP4
Download video MP3
Similar videos
-
2:51
highlights on adjuvant alectinib in early alk positive nsclc: the alina study
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
2:37
alectinib for the treatment of nsclc: an update on the alina trial
-
7:32
adjuvant alectinib vs. chemotherapy in early-stage alk nsclc: dr. amit kumar's analysis | crsf
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
1:13
the alina trial for alk nsclc
-
1:39
key findings of the alex study: improved therapeutic options for alk-positive nsclc
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
1:22
assessing the efficacy of alectinib versus crizotinib in alk-positive nsclc
-
0:54
the alina trial for alk nsclc - targeted therapies in lung cancer 2023
-
3:27
trial updates in neoadjuvant adjuvant therapies for early-stage nsclc
-
4:00
alectinib eclipses crizotnib for alk positive lung cancer
-
1:56
alex: alectinib is the best first-line therapy available for alk-positive nsclc
-
6:51
progression in alk nsclc after frontline therapy
-
5:42
gracecast - lcvl- what are the options after a patient with an alk-positive advanced nsclc develops
-
1:24
choosing the best alk inhibitor for lung cancer
-
3:43
bfast: high dose alectinib for ret-positive nsclc
-
2:13
alk nsclc: brigatinib indication and alta trial
-
1:01
targeting alk rearrangements in non-small cell lung cancer